Current Pharmaceutical Design

William A. Banks  
VAPSHCS/GRECC S-182
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108
USA

Back

Pharmacogenetics and Drug Therapy in Psychiatry - The Role of the CYP2D6 Polymorphism

Author(s): P. Vandel, J. M. Talon, E. Haffen and D. Sechter

Affiliation: Service de Psychiatrie et Psychologie Medicale, CHU 25030 Besancon France.

Keywords: Pharmacogenetics, metabolic polymorphism, CYP2D6, therapeutic implications

Abstract:

The importance of pharmacogenetics in medicine is growing with the identification of genetic variability by faster screening methods using automatic sequencers. A particularly interesting finding is that apart from environmental and psychological factors, drug response may be influenced by several biological factors as a result of genetic determinants leading to interindividual variability. Several mutations in genes coding for enzymes of the drug metabolizing system, as well as for neurotransmitter receptors or degrading enzymes and monoamine transport proteins, have been identified and investigated in psychiatry. But, despite the fact that some genetic polymorphisms of enzymes (mainly cytochrome P450 2D6) are well known, the application of pharmacogenetics as a therapeutic tool for improving patient care is rare. This review has three parts. In the first an overview is given of CYP450 characteristics and the genetic polymorphisms of interest to psychiatry. In the second the clinical implications of the CYP2D6 polymorphism are reviewed and in the third part other aspects on pharmacogenetic research in psychiatry are discussed. The aim of our review is to promote the application of pharmacogenetics in everyday clinical practice.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 13
ISSUE: 2
Page: [241 - 250]
Pages: 10
DOI: 10.2174/138161207779313704